CymaBay Therapeutics Inc. (CBAY) Social Stream



CymaBay Therapeutics Inc. (CBAY): $4.25

0.13 (+3.16%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CBAY to Watchlist
Sign Up

Industry: Biotech


Ranked

of 402

in industry

CymaBay Therapeutics Inc (CBAY) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering CBAY.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-10-17 8 $14 $7 $11.125 $3.39 228.17%
2021-11-11 8 $14 $7 $11.25 $3.39 231.86%
2022-03-18 7 $14 $10 $11.714 $3.39 245.55%
2022-03-29 7 $14 $9 $11.375 $3.39 235.55%

The Trend in the Analyst Price Target


CBAY's average price target has moved up $0.57 over the prior 28 weeks.

CBAY reports an average of 203.11% for its upside potential over the past 48 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-06-13 4 15 7 12.000 4.68 156.41%
2021-08-05 11 15 7 11.500 3.93 192.62%
2021-08-09 11 15 7 11.500 3.89 195.63%
2021-09-11 11 14 7 10.800 3.89 177.63%
2022-03-18 8 14 10 11.714 3.15 271.87%

CBAY Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 7 0 0 0 0 7

The Trend in the Broker Recommendations


Over the past 18 months, CBAY's average broker recommendation rating improved by 0.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • CBAY has a higher upside potential (average analyst target price relative to current price) than 543.1% of all US stocks.
  • CymaBay Therapeutics Inc's average analyst price target is greater than 64.33% of all US stocks.
  • In the context of stocks in the small market cap category, CymaBay Therapeutics Inc's number of analysts covering the stock is greater than 543.94% of them.
  • In the context of stocks in the small market cap category, CymaBay Therapeutics Inc's variance in analysts' estimates is lower than -283.35% of them.

Stocks similar to CymaBay Therapeutics Inc in the Pharmaceutical Products industry regarding analyst recommendations and price targets are CARA, CANF, and CALT.

Is CBAY a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4994 seconds.